key: cord-0776014-x110iuix
authors: Cordero, Alberto; García-Gallego, Carlos Santos; Bertomeu-González, Vicente; Fácila, Lorenzo; Rodríguez-Mañero, Moisés; Escribano, David; Castellano, José M.; Zuazola, Pilar; Núñez, Julio; Badimón, Juan J.; Ramón González-Juanatey, José
title: Mortality associated with cardiovascular disease in patients with COVID-19
date: 2020-10-26
journal: nan
DOI: 10.1016/j.rccl.2020.10.005
sha: 986bb07c7d6cb9dd1739b2d4875ba8babf74ede1
doc_id: 776014
cord_uid: x110iuix

Introduction and objectives: Cardiovascular disease (CVD) has been outlined as a possible risk factor for poorer outcomes in patients with COVID-19 infection. Methods: A meta-analysis was performed with currently available studies that report the prevalence of CVD in survivors vs non-survivors in patients with COVID-19 infection using reports available at 16 July 2020. Analyses were performed by a random effects model and sensitivity analyses were performed for the identification of potential sources of heterogeneity or assess the small-study effects. Results: A total of 307 596 patients from 16 reports were included and 46 321 (15.1%) had CVD. Globally, mortality rate was 8.2% (20 534 patients) and mortality rates were higher in hospital registries (48.7%) compared to national reports (23.1%). A total of 11 213 (24.2%) patients with CVD died and mortality rates were also higher in hospital registries (48.7%) compared to national reports (23.1%). CVD was associated to 4-fold higher risk of mortality (OR, 4.33; 95%CI, 3.16-5.94). Data from 28 048 patients with diabetes was available. Diabetes was associated to higher mortality risk (OR, 2.41; 95%CI, 1.79-3.26; P < .001). From 40 173 subjects with hypertension it could also be proven a risk factor for higher mortality (OR, 2.60; 95%CI, 2.10-3.21; P < .001). Conclusions: patients with CVD and COVID-19 infection have 4-fold higher risk of death. Diabetes or hypertension are also associated with higher mortality risk.

After the outbreak of the novel coronavirus in China, the coronavirus desease 2019 (COVID- 19) , and its worldwide spread, the World Health Organization (WHO) declared its incidence as pandemic in February 2020. 1 The lack of reliable information lead to early and worthy reports of clinical features 2,3 and mortality rates. [4] [5] [6] [7] Most initial clinical data came from hospital registries and, therefore, reflected the inhospital course and mortality of patients with COVID-19 infection. 8 By the end of April, the pandemic had widely affected Europe and more than 50 000 patients had died. 9, 10 Although most patients with COVID-19 infection develop mild symptoms, a relevant percentage that can be from 15 to 20%, develop pulmonary insufficiency and systemic symptoms that require hospitalization or intensive care treatments. 2, 3, [11] [12] [13] [14] To elucidate what are the risk factors for severe illness or death remains a clinical challenge. [15] [16] [17] Patients with cardiovascular disease (CVD) are at increased risk of infections and have higher mortality rates for infectious diseases. 18 Comorbidities, and specially age or CVD, have been outlined as a risk factor for poorer outcomes in COVID-19 patients from the first reports [4] [5] [6] [7] 19 and also in european cohorts. 20 In collaboration with National Health Commission of China from China a risk score to predict severe COVID-19 disease has been recently developed and validated that includes CVD as one of the qualifying comorbidities. 21 Our study aimed to describe and define the risk of patients with CVD and COVID-19 infection.

We performed a meta-analysis in line with recommendations from the Cochrane Collaboration and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement 22 (table 1 of the supplementary data). We made a systematic search (using PUBMED, EMBASE, and Cochrane Central Register of Controlled Trials [CENTRAL], and Google Scholar), without language restriction, for papers using the Medical Subject Headings terms "Coronavirus," "COVID-19", "Mortality, "Clinical outcomes"

and "Clinical course" up to 25 July 2020. We also reviewed all institutional websites to obtain national reports of coronavirus. Primary outcome was all cause-death. As a result 16 studies that reported clinical patients who died vs survivors were identified: 16 were hospital registries 4-7, 17, 19, 20, 23-31 and   2 were national reports (one from China 32 and other from Spain. 10 ) Two hospital registries were not included in the metanalysis, One hospital registry included only patients with CVD, 7 and it was not included in the analysis. The study by Mehra et al. 17 was excluded since results were withdrawed from the journal. National reports from Italy 33 , Germany 34 , UK 35 , Belgium 36 and France 37 did not report the prevalence of CVD in patients who died from COVID. Therefore, analyses were performed using 16 reports (2 national reports and 14 hospital registries). CVD included coronary heart disease, heart failure, and cerebrovascular disease. For the eligible studies, two authors independently abstracted data into a standardized form; discrepancies in data extraction and quality assessment were resolved by discussion or consensus with a third author.

Clinical features and in-hospital mortality were available all studies. Relative risk reductions and percent incidences were used. The study-specific standard errors for the estimated relative risks were used to model the within-study variation. The percentage of variability across studies attributable to heterogeneity beyond chance was estimated using the I 2 statistic. Once heterogeneity was observed and assuming that the study effect sizes were different and that the collected studies represented a random sample from a larger population, all the analyses were performed by a random effects model. Sensitivity analyses were performed for the identification of potential sources of heterogeneity between trials with meta-regression analyses and Harbord test, to assess the small-study effects. 33 A total of 11 213 (24.2%) patients with CVD died and mortality rates were also higher in hospital 7 registries (48.7%; 988/2 028) compared to national reports (23.1%; 10 225/44 293). CVD was associated to 4-fold higher risk of mortality (OR, 4.33; 95%CI, 3.16-5.94) ( Fig. 1) 4, 24, 6, 19, 5, 26, 23, 25, 20, 27, 28, 30, 29 . Significant heterogeneity was observed between both types of reports and hospital registries reports. The scatter wide distribution in the funnel plot suggested the presence of reporting bias ( Fig. 2A ) but the smallstudy effect was excluded by the Harbord test (P = .48). Meta-regression analysis identified age (P < .001), fatality rates (P = 0.04) and prevalence of CVD and 2 outlier results 6, 26 as the main sources of heterogeneity.

We also analyzed the effect of CVD risk factors on mortality. Data from 28 048 patients with diabetes was available. Diabetes was associated to higher mortality risk (OR, 2.41; 95%CI; 1.79-3.26; P < .001) ( Fig. 3 ) 30, 4, 20, 23, 19, 5, 31, 26, 24, 25, 6, 28, 29 . Age (P < .01) and data source (P = .026) were the leading causes of heterogenicity (Fig. 2B) . Sensitivity analyses suggested bias in the results of patients with diabetes; the funnel plot was not symmetrical and had a disperse distribution (Fig. 2B ) and the Harbor test suggested a small-trial effect (P = .01). As shown in Fig. 4 24, 6, 19, 5, 26, 23, 25, 20, 28, 30, 29, 31 , hypertension was also associated to higher risk of death (OR, 2.60; 95%CI, 2.10-3.21; P < .001). In contrast, the funnel plot was more symmetrical and had less dispersion (Fig. 2C) ; moreover, the Harbor test excluded relevant biases or small-study effect (P = .39).

The metanalysis of currently available data suggests that patients with CVD and COVID-19 infection have more than 4-fold higher risk of mortality. Our results may have several clinical implications such as more strict measures for prevention of COVID-19 infection in patients with CVD as well as early and aggressive management of infected patients. 38 COVID-19 pandemic has irrupted in the medical community in terms of diagnosis, contention, and clinical management. 15, 16, 39 The worldwide spread has increased the urgent need for relevant data; the meritorious reports from China were very illustrative and national reports have progressively increased the knowledge of this unpreceded outbreak. spectrum of disease, how transmissible it is, identification of the infectors and, defining the risk factors for severe illness or death. 15 CVD was outlined as a risk factor for poorer outcomes, from the first reports, 5-7, 19, 40 and we conducted this metanalysis under the awareness of the large, and increasing, the prevalence of patients with CVD worldwide. 41, 42 Our results suggest that patients with CVD have more than 4-fold higher risk of death once they get the COVID-19 infection. Clinical variables associated with poor in-hospital outcomes highlighted CVD as one them. 6, 7 The National Health Commission of China designed and validated a risk score to predict severe COVID-19 disease, a combined end-point that included admission to the intensive care unit, invasive ventilation, or death. 21 Our results might reflect that CVD should be taken as a relevant and independent risk factor in COVID-19 patients. We found differences in mortality rates between hospital registries and national reports but the risk associated with CVD was similar in both types of reports, what might reflect the reliability of national reports and endorse our results. Nonetheless, most clinical series had small sample sizes and were underpowered to assess the actual risk of death associated with CVD in COVID-19 patients. At least 2 hospital series have analyzed the impact of CVD on COVID-19 patients. A report from 99 patients admitted in Northern hospitals, with only 53 patients with CVD, found higher mortality rates in an univariate analysis. 20 A larger report with 522 patients from 2 Spanish hospitals described an independent association of CVD only with the combined end-point of death or respiratory insufficiency. 27 The fact that both series were underpowered to achieve statistically significant results reinforces the need of our metanalysis.

The mechanisms that could explain the increased risk of death in CVD patients are not fully known. 43, 44 Patients with severe pneumonia, previous CVD, and older age are at higher risk of developing cardiac complications during and after pneumonia. 18 Cardiac injury was detected in 19.7% of patients admitted with COVID-19 symptoms and it was associated with higher risk of in-hospital mortality (HR, 4.26; 95%CI, 1.92-9.49) in a single center study form Wuham. 45 A recent meta-analysis showed that myocardial injury could be detected in 21% of COVID-19 patients and it was 4-fold higher in severe patients. 46 More interestingly, myocardial injury has been reported as an equivalent to previous myocardial infarction in terms of mortality risk in COVID-19 patients. 47 Prolonged fever and pro-inflammatory state are poorly tolerated in patients with CVD and, therefore, acute respiratory distress syndrome and respiratory failure, sepsis, acute cardiac injury, and heart failure, the most severe and common complications during exacerbation of COVID-19, are busted in patients with CVD. 19, 24, 39, 46, 48, 49 Low levels of highdensity lipoprotein cholesterol (HDLc) have been clearly related to DM and cardiovascular disease 50 and recent studies have linked low HDLc to higher risk of severe Patients with CVD have a high prevalence of cardiovascular risk factors 52 and it can, also, impair their prognosis. Our results also describe a significant effect of hypertension and diabetes on mortality. The antecedent of hypertension could not be analyzed in the Spanish national report because it was only registered from 18 March 2020. 10 Hypertension and, more especially treatment in angiotensin-receptor blockers or angiotensin receptor antagonist, has received great interest because the COVID-19 virus is known to infect cells by the angiotensin receptor; 53 nonetheless, there is no solid evidence to withdraw this treatment. 45, 54, 55 Regardless of this treatment debate, our results found a clear increased risk of patients with hypertension or diabetes, that was even higher in national reports. Since significant heterogeneicity was observed in our results we conducted sensitivity analyses and excluded the smallstudies effect; 38 nonetheless, is difficult to be certain whether publication bias or studies' sample size were the most determinant issue because of the presence of substantial heterogeneity. Diabetes is a well-stablished risk factor for CVD and atherosclerosis and recent metanalysis described an increased risk of mortality associated with DM (OR, 1.75; 95%CI, 1.31-2.36; P = .0002) 56 and our study, with much more studies and patients, fully agree with those findings.

National reports have been providing rapid and large-scale data from COVID-19 incidence and mortality and, in many cases, other relevant information. National reports have been previously used to analyse the effect of age on mortality in COVID-19 patients and demonstrated that age > 50 is the threshold for increased mortality risk. 57 In this new metanalysis, we used the national COVID-19 report from Spain that included the percentage of patients with CVD and their mortality rates as well as many other Page 10 of 24 J o u r n a l P r e -p r o o f 10 comorbities. It should be noted that mortality risk associated with CVD in the Spanish and Chinese reports were identical and it should reflect the reliability of these data sources. Nonetheless, reports included only patients with confirmed infection that were tested before hospital admission and, therefore, they might reflect only most severe or clinically relevant cases. The criteria for testing, especially in the initial phases of the pandemic, were very different in each region and this was suggested as a key element for the differences in mortality rates. 9 We believe that our results could reinforce the key role of infection prevention in patients with CVD but also, to implement rapid and aggressive diagnosis and treatment in these patients. 16 

Our study has several limitations, mainly derived from the limited evidence available. Moreover, reports were based only on patients with laboratory-confirmed infection. Second, official and published data were used and we could not split the effect of different modalities of cardiovascular disease. Third, these findings are probably limited to the most severe patients (those that are finally diagnosed due to symptoms). Fourth, the prevalence of obesity was not reported in the publications and, therefore, the impact of excess of weight and its relationship with DM and other clinical features of the metabolic syndrome could not be analyzed. Finally, most national reports do not include the prevalence of CVD or the differential features of patients who died vs survivors. The National Report from Spain represented most patients in the study and in the sub-group of national reports and, therefore, results might not be Page 11 of 24 J o u r n a l P r e -p r o o f 11 representative world-wide. We believe that these limitations might had a minimal effect on results representative and, moreover, might reinforce the need of fast-track publication of reports and clinical registries reporting such valuable data despite the hard conditions.

In conclusion, the metanalysis of 305 370 patients highlights that patients with CVD and COVID-19

infection have more than 4-fold higher risk of mortality, as well as patients with hypertension or diabetes. More clinical and basic research is needed for elucidate the mechanism involved in the cardiovascular manifestations in COVID-19 infected patients and strategies to improve infections and outcomes in CVD patients. Our results should be taken under consideration for future surges of the pandemic in order to implement preventive measures in patients with CVD.

Authors have no conflict of interest related to the results of this study.

Investigators received the support from the Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV CB16/11/00226 -CB16/11/00420).

What is known about the subject? -Patients with CVD are at increased risk of infections and have higher mortality rates for infectious diseases.

-Comorbidities, specially age or CVD, have been outlined as a risk factors for poorer outcomes in COVID-

Does it contribute anything new?

-Patients with CVD with and COVID-19 infection have 4-fold higher risk of death.

-Diabetes or hypertension are associated with twice higer mortality risk CVD in COVID-19. 

Coronavirus disease (COVID-19) outbreak

China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics and outcomes of 112

cardiovascular disease patients infected by 2019-nCoV

Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic

Case-Fatality Rate and Characteristics of Patients Dying in

European Patients with mild-to-moderate Coronavirus Disease

OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients

Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom

Defining the Epidemiology of Covid-19 -Studies Needed

COVID-19-New Insights on a Rapidly Changing Epidemic

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Pneumonia as a cardiovascular disease

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy

Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Metaanalyses

Suspected myocardial injury in patients with COVID-19: Evidence from front-line clinical observation in Wuhan, China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Association of Treatment With Hydroxychloroquine or

Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study

La presencia de cardiopatía agrava el pronóstico de los pacientes con COVID-19

Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe

The Novel Coronavirus Pneumonia Emergency Response Epidemiology T. Vital Surveillances: The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) -China

COVID-19 integrated surveillance: key national data

Aktueller Lage-/Situationsbericht des RKI zu COVID-19

National COVID-19 surveillance reports

COVID-19 -Situation épidémiologique

Coronavirus : chiffres clés et évolution de la COVID-19 en France et dans le

Emerging cardiological issues during the COVID-19 pandemic

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic

European Society of Cardiology: Cardiovascular Disease Statistics

Coronaviruses and the cardiovascular system: acute and long-term implications

COVID-19 and cardiovascular diseases

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Incidence of myocardial injury in coronavirus disease

COVID-19): a pooled analysis of 7,679 patients from 53 studies

Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19)

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore

Las concentraciones bajas de colesterol unido a las lipoproteínas de alta densidad se asocian de manera independiente a enfermedad coronaria aguda en pacientes que ingresan por dolor torácico

Low high-density lipoprotein level is correlated with the severity of COVID-19 patients: an observational study

Trends in Risk Factors and Treatments in Patients With Stable Ischemic Heart Disease Seen at Cardiology Clinics Between

Pathology and Pathogenesis of Severe Acute Respiratory Syndrome

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Impact of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on COVID-19 in a western population

Diabetes increases the mortality of patients with COVID-19: a metaanalysis

The Effect of Age on Mortality in

Patients With COVID-19: A Meta-Analysis With 611,583 Subjects

Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area

ES. Rosenberg 25